343P - The role of clinical characteristics in low grade gliomas in molecular era

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Central Nervous System Malignancies
Presenter Antonella Mura
Citation Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366
Authors A. Mura1, E. Franceschi1, S. Minichillo1, A. Mandrioli1, A. Tosoni1, A. Fioravanti1, A. Talacchi2, L. Volpin3, G. Tallini4, D. De Biase4, R. Agati5, S. Pizzolitto6, S. Bartolini1, A. Paccapelo1, A.A. Brandes1
  • 1Medical Oncology, Ausl / Irccs Institute Of Neurological Sciences, Bellaria Hospital, 40139 - Bologna/IT
  • 2Department Of Neurological, Neuropsychological, Morphological And Movement Sciences, Section Of Neurosurgery, University of Verona, University Hospital, Verona/IT
  • 3Neuroscience And Neurosurgery, San Bortolo Hospital, Vicenza/IT
  • 4Department Of Biomedical And Neuromotor Sciences (dibinem), Section Of Pathology, M. Malpighi, Bellaria Hospital, University of Bologna, Bologna/IT
  • 5Department Of Neuroradiology, Bellaria Hospital, IRCCS Institute of Neurological Sciences, Bologna/IT
  • 6Department Of Pathology, Santa Maria della Misericordia Hospital, Udine/IT

Abstract

Background

Low grade gliomas (LGGs) are rare tumors. Molecular characterization has been recently integrated into diagnostic workup of low grade gliomas (LGG) defining specific prognostic features. Moreover, clinical factors, such as age and the extent of resection have a prognostic role in LGG. Here we report a comprehensive analysis on clinical and molecular features impacting on outcome in a large cohort of LGG.

Methods

We evaluated adult LGG patients (pts) which occurred from 1991 to 2015, who received surgery and had sufficient tissue to assess molecular biomarkers characterization. We assessed the status of IDH mutation (using PCR or NGS) 1p19q codeletion (FISH), MGMT methylation (detected with PCR).

Results

213 consecutive LGG were included. The median age was 38 (range:18–69). Median follow up was 98.3 months, 25 pts (11.7%) underwent biopsy, 124 pts (58.2%) subtotal resection, 64 pts (30%) grosstotal resection. According to RTOG criteria 37pts (17.4%) were low-risk (

Conclusions

The definition of LGG outcome is complex. Both clinical and molecular factors are needed to determine prognosis and treatment strategies.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.